These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 15243303)
21. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Kerenyi Z; Samer H; James R; Yan Y; Stewart M Diabetes Res Clin Pract; 2004 Mar; 63(3):213-23. PubMed ID: 14757293 [TBL] [Abstract][Full Text] [Related]
22. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Garber A; Klein E; Bruce S; Sankoh S; Mohideen P Diabetes Obes Metab; 2006 Mar; 8(2):156-63. PubMed ID: 16448519 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416 [TBL] [Abstract][Full Text] [Related]
24. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190 [TBL] [Abstract][Full Text] [Related]
25. Effect of cilazapril on glucose tolerance and lipid profile in hypertensive patients with non-insulin-dependent diabetes mellitus. Gans RO; Stehouwer CD; Bilo HJ; Goggin T; Kraaij CJ; Donker AJ; van der Veen EA Neth J Med; 1993 Oct; 43(3-4):163-73. PubMed ID: 8302395 [TBL] [Abstract][Full Text] [Related]
27. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158 [TBL] [Abstract][Full Text] [Related]
28. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090 [TBL] [Abstract][Full Text] [Related]
29. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. Chogtu B; Singh NP; Chawla S; Gupta U Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684 [TBL] [Abstract][Full Text] [Related]
30. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. St John Sutton M; Rendell M; Dandona P; Dole JF; Murphy K; Patwardhan R; Patel J; Freed M Diabetes Care; 2002 Nov; 25(11):2058-64. PubMed ID: 12401757 [TBL] [Abstract][Full Text] [Related]
31. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727 [TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Raji A; Seely EW; Bekins SA; Williams GH; Simonson DC Diabetes Care; 2003 Jan; 26(1):172-8. PubMed ID: 12502676 [TBL] [Abstract][Full Text] [Related]
33. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152 [TBL] [Abstract][Full Text] [Related]
34. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. Zhu XX; Pan CY; Li GW; Shi HL; Tian H; Yang WY; Jiang J; Sun XC; Davies C; Chow WH Diabetes Technol Ther; 2003; 5(1):33-42. PubMed ID: 12725705 [TBL] [Abstract][Full Text] [Related]
35. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. de Rivas B; Luque M; Martell N; Fernández C; Fernández-Cruz A J Clin Hypertens (Greenwich); 2007 Jul; 9(7):530-7. PubMed ID: 17617763 [TBL] [Abstract][Full Text] [Related]
36. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Chiquette E; Ramirez G; Defronzo R Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122 [TBL] [Abstract][Full Text] [Related]
37. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505 [TBL] [Abstract][Full Text] [Related]
38. [Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension]. Li GW; Wang JP; Li CM; Chen YY; Yang WY; Xing XY; Liu KL; Tang YL; Li H Zhonghua Nei Ke Za Zhi; 2004 Dec; 43(12):907-10. PubMed ID: 15730735 [TBL] [Abstract][Full Text] [Related]
39. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Natali A; Baldeweg S; Toschi E; Capaldo B; Barbaro D; Gastaldelli A; Yudkin JS; Ferrannini E Diabetes Care; 2004 Jun; 27(6):1349-57. PubMed ID: 15161787 [TBL] [Abstract][Full Text] [Related]
40. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]